Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia

Psychoneuroendocrinology

Volumn 32, Issue 4, 2007, Pages 385-391

  Ko, Young Hoon ^a   Jung, Sung Won ^b   Joe, Sook Haeng ^a   Lee, Chang Hyun ^b   Jung, Hyun Gang ^a   Jung, In Kwa ^a   Kim, Seung Hyun ^a   Lee, Moon Su ^a  

^a Korea University College of Medicine   (South Korea)

^b Bugok National Hospital   (South Korea)

Author keywords

Free testosterone; Negative symptoms; Schizophrenia; Testosterone

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; ESTRADIOL; OLANZAPINE; PRASTERONE SULFATE; PROLACTIN; QUETIAPINE; RISPERIDONE; TESTOSTERONE; ZOTEPINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY FAT; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; HOSPITAL PATIENT; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MALE; MENTAL PATIENT; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TESTOSTERONE BLOOD LEVEL;

ADULT; CHRONIC DISEASE; HUMANS; MALE; RESEARCH DESIGN; SCHIZOPHRENIA; TESTOSTERONE;

EID: 34247281469     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2007.02.002     Document Type: Article

References (54)

1. Addington D., Addington J., and Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 3 (1990) 247-251
2. Akhondzadeh S., Rezaei F., Larijani B., Nejatisafa A.A., Kashani L., and Abbasi S.H. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr. Res. 8 (2006) 405-410
3. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
4. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry 39 (1982) 784-788
5. Bialek M., Zaremba P., Borowicz K.K., and Czuczwar S.J. Neuroprotective role of testosterone in the nervous system. Pol. J. Pharmacol. 56 (1997) 509-518
6. Bremner W.J., Vitiello M.V., and Prinz P.N. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J. Clin. Endocrinol. Metab. 56 (1983) 1278-1281
7. Brophy M.H., Rush A.J., and Crowley G. Cortisol, estradiol, and androgens in acutely ill paranoid schizophrenics. Biol. Psychiatry 18 (1983) 583-590
8. Brown S., Birtwistle J., Roe L., and Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 29 (1999) 697-701
9. Carpenter Jr. W.T., Heinrichs D.W., and Alphs L.D. Treatment of negative symptoms. Schizophr. Bull. 11 (1985) 440-452
10. Chatterjee S., Patel V., Chatterjee A., and Weiss H. Evaluation of a community-based rehabilitation model for chronic schizophrenia in rural India. Br. J. Psychiatry 182 (2003) 57-62
11. Christiansen K., Knussmann R., and Couwenbergs C. Sex hormones and stress in the human male. Horm. Behav. 19 (1985) 426-440
12. Coodin S. Body mass index in persons with schizophrenia. Can. J. Psychiatry 46 (2001) 549-555
13. de Leon J., Wilson W.H., and Simpson G.M. Measurement of negative symptoms in schizophrenia. Psychiatr. Dev. 7 (1989) 211-234
14. Deslypere J.P., and Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J. Clin. Endocrinol. Metab. 59 (1984) 955-962
15. Dollfus S., Ribeyre J.M., and Petit M. Objective and subjective extrapyramidal side effects in schizophrenia: their relationships with negative and depressive symptoms. Psychopathology 33 (2000) 125-130
16. Dunn J.F., Nisula B.C., and Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab. 53 (1981) 58-68
17. El-Sayeh H.G., Morganti C., and Adams C.E. Aripiprazole for schizophrenia. Systematic review. Br. J. Psychiatry 189 (2006) 102-108
18. Giorgi E.P., and Stein W.D. The transport of steroids into animal cells in culture. Endocrinology 108 (1981) 688-697
19. Gooren L.J., and Toorians A.W. Significance of oestrogens in male (patho)physiology. Ann. Endocrinol. (Paris) 64 (2003) 126-135
20. Goyal R.O., Sagar R., Ammini A.C., Khurana M.L., and Alias A.G. Negative correlation between negative symptoms of schizophrenia and testosterone levels. Ann. N.Y. Acad. Sci. 1032 (2004) 291-294
21. Gray A., Feldman H.A., McKinlay J.B., and Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 73 (1991) 1016-1025
22. Harris D.S., Wolkowitz O.M., and Reus V.I. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J. Biol. Psychiatry 2 (2001) 99-102
23. Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on DIEPSS and guide to its usage (1996), Seiwa Shoten Publishers, Tokyo
24. Jannini E.A., Screponi E., Carosa E., Pepe M., Lo G.F., Trimarchi F., et al. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int. J. Androl. 22 (1999) 385-392
25. Kaneda Y. Effects of risperidone on gonadal axis hormones in schizophrenia. Ann. Pharmacother. 35 (2001) 1523-1527
26. Kaneda Y. The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia. Clin. Neuropharmacol. 26 (2003) 182-184
27. Kaneda Y., and Fujii A. Effects of chronic neuroleptic administration on the hypothalamo-pituitary-gonadal axis of male schizophrenics. Prog. Neuropsychopharmacol. Biol. Psychiatry 24 (2000) 251-258
28. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
29. Labrie F., Belanger A., Cusan L., Gomez J.L., and Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab. 82 (1997) 2396-2402
30. Lieberman J.A., Sheitman B.B., and Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacol 17 (1997) 205-229
31. Mason J.W., Giller E.L., and Kosten T.R. Serum testosterone differences between patients with schizophrenia and those with affective disorder. Biol. Psychiatry 23 (1988) 357-366
32. Mason J.W., Kosten T.R., and Giller E.L. Multidimensional hormonal discrimination of paranoid schizophrenic from bipolar manic patients. Biol. Psychiatry 29 (1991) 457-466
33. McEwen B.S. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol. Sci. 12 (1991) 141-147
34. McEwen B.S., and Alves S.E. Estrogen actions in the central nervous system. Endocr. Rev. 20 (1999) 279-307
35. Melkersson K.I., Hulting A.L., and Rane A.J. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br. J. Clin. Pharmacol. 51 (2001) 317-324
36. Molitch M.E. Disorders of prolactin secretion. Endocrinol. Metab. Clin. North Am. 30 (2001) 585-610
37. Oades R.D., and Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology 19 (1994) 373-385
38. Orentreich N., Brind J.L., Rizer R.L., and Vogelman J.H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59 (1984) 551-555
39. Prosser E.S., Csernansky J.G., Kaplan J., Thiemann S., Becker T.J., and Hollister L.E. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J. Nerv. Ment. Dis. 175 (1987) 100-105
40. Rinieris P., Hatzimanolis J., Markianos M., and Stefanis C. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients. Neuropsychobiology 22 (1989) 146-149
41. Ritsner M., Gibel A., Ram E., Maayan R., and Weizman A. Alterations in DHEA metabolism in schizophrenia: two-month case-control study. Eur. Neuropsychopharmacol. 2 (2005) 137-146
42. Ritsner M., Maayan R., Gibel A., Strous R.D., Modai I., and Weizman A. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur. Neuropsychopharmacol. 14 (2004) 267-273
43. Rau M.L., and Kölsch H. Effect of estrogen on brain development and neuroprotection-implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 28 (2003) 83-96
44. Seidman S.N., and Walsh B.T. Testosterone and depression in aging men. Am. J. Geriatr. Psychiatry 7 (1999) 18-33
45. Shirayama Y., Hashimoto K., Suzuki Y., and Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr. Res. 58 (2002) 69-74
46. Sommers A.A. "Negative symptoms": conceptual and methodological problems. Schizophr. Bull. 11 (1985) 364-379
47. Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am. J. Psychiatry 155 (1998) 1310-1318
48. Steven J.R. Schizophrenia: reproductive hormones and the brain. Am. J. Psychiatry 159 (2002) 713-719
49. Strous R.D., Maayan R., Lapidus R., Goredetsky L., Zeldich E., and Kotler M.etal. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr. Res 71 (2004) 427-434
50. Taherianfard M., and Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J. Med. Sci. 58 (2004) 3-9
51. Van Putten T. Why do schizophrenic patients refuse to take their drugs?. Arch. Gen. Psychiatry 31 (1974) 67-72
52. Wieck A., and Haddad P.M. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: selective literature review. Br. J. Psychiatry 182 (2003) 199-204
53. Zmuda J.M., Thompson P.D., and Winters S.J. Exercise increases serum testosterone and sex hormone-binding globulin levels in older men. Metabolism 45 (1996) 935-939
54. Zumoff B., Strain G.W., Miller L.K., Rosner W., Senie R., and Seres D.S.etal. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J. Clin. Endocrinol. Metab. 71 (1990) 929-931